Trial Profile
A Prospective, Proof-of-Concept Study Evaluating the Administration of Pegloticase (Krystexxa) with the Immunomodulator Methotrexate to Improve the Durability of KRYSTEXXA Response in Patients with Refractory Gouty Arthropathy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs Methotrexate (Primary) ; Pegloticase (Primary) ; Folic acid
- Indications Gout
- Focus Proof of concept; Therapeutic Use
- 10 Oct 2020 Results published in the JCR: Journal of Clinical Rheumatology
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 29 Nov 2018 New trial record